Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据

2019-04-13 不详网络

Alligator Bioscience公司近日宣布，CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据已经发表在《Journal for ImmunoTherapy of Cancer》杂志上。

Alligator Bioscience公司近日宣布，CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据已经发表在《Journal for ImmunoTherapy of Cancer》杂志上。已发表的数据显示，ATOR-1015在几种实验性肿瘤模型（包括膀胱癌，结肠癌和胰腺癌）中具有抗肿瘤作用。此外，数据表明ATOR-1015与PD-1阻断疗法的组合能够诱导长期免疫记忆以及增强的抗肿瘤反应。

该数据支持了ATOR-1015的持续临床开发，目前正在进行I期研究（NCT03782467），这项研究的结果预计将在2020年下半年公布。

原始出处：

http://www.firstwordpharma.com/node/1634983#axzz5kmtmGZrh

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1797297, encodeId=01ec1e97297ad, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Oct 25 15:05:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13562, encryptionId=dd5813562e5, topicName=OX40)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Wed Nov 20 16:05:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899288, encodeId=7d99189928801, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 09 14:05:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Wed Dec 04 06:05:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526447, encodeId=f408152644e60, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
2019-10-25 cqlidoudou

#临床前数据#

74 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1797297, encodeId=01ec1e97297ad, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Oct 25 15:05:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13562, encryptionId=dd5813562e5, topicName=OX40)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Wed Nov 20 16:05:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899288, encodeId=7d99189928801, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 09 14:05:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Wed Dec 04 06:05:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526447, encodeId=f408152644e60, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
2019-11-20 ms3830150583600765

#OX40#

96 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1797297, encodeId=01ec1e97297ad, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Oct 25 15:05:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13562, encryptionId=dd5813562e5, topicName=OX40)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Wed Nov 20 16:05:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899288, encodeId=7d99189928801, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 09 14:05:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Wed Dec 04 06:05:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526447, encodeId=f408152644e60, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
2020-03-09 jinweidong

#特异性#

61 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1797297, encodeId=01ec1e97297ad, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Oct 25 15:05:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13562, encryptionId=dd5813562e5, topicName=OX40)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Wed Nov 20 16:05:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899288, encodeId=7d99189928801, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 09 14:05:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Wed Dec 04 06:05:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526447, encodeId=f408152644e60, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
2019-12-04 124988c7m106暂无昵称

#ERA#

83 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1797297, encodeId=01ec1e97297ad, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Oct 25 15:05:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13562, encryptionId=dd5813562e5, topicName=OX40)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Wed Nov 20 16:05:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899288, encodeId=7d99189928801, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 09 14:05:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Wed Dec 04 06:05:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526447, encodeId=f408152644e60, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
2019-04-15 hywen7328

#CTLA-4#

75 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1797297, encodeId=01ec1e97297ad, content=<a href='/topic/show?id=a51422e0639' target=_blank style='color:#2F92EE;'>#临床前数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22706, encryptionId=a51422e0639, topicName=临床前数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Fri Oct 25 15:05:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13562, encryptionId=dd5813562e5, topicName=OX40)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Wed Nov 20 16:05:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899288, encodeId=7d99189928801, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 09 14:05:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738947, encodeId=3de61e389471b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Wed Dec 04 06:05:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461867, encodeId=bf14146186e99, content=<a href='/topic/show?id=4440540855' target=_blank style='color:#2F92EE;'>#CTLA-4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5408, encryptionId=4440540855, topicName=CTLA-4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c46457704, createdName=hywen7328, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526447, encodeId=f408152644e60, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Mon Apr 15 07:05:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
2019-04-15 hyf032

#特异性抗体#

62 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化

Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据

相关资讯

科室

工具

服务